Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients

D. Danila, A. Samoila, C. Patel, N. Schreiber, Amrita Herkal, A. Anand, D. Bastos, G. Heller, M. Fleisher, H. Scher
{"title":"Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients","authors":"D. Danila, A. Samoila, C. Patel, N. Schreiber, Amrita Herkal, A. Anand, D. Bastos, G. Heller, M. Fleisher, H. Scher","doi":"10.1097/PPO.0000000000000220","DOIUrl":null,"url":null,"abstract":"AbstractCirculating tumor cell (CTC) number measured with the CellSearch assay is prognostic for survival in metastatic castration-resistant prostate cancer before and after therapy. Using a standard operating protocol for sample collection, processing, and analysis, we compared detection rates of CellSearch performed using US Food and Drug Administration–cleared methodology with a second positive selection assay, AdnaTest, and a nonselection polymerase chain reaction (PCR)–based (direct detection PCR [DDPCR]) assay in 55 blood samples from 47 men with progressive metastatic castration-resistant prostate cancer. AdnaTest requires processing within 4 hours of the draw and detects KLK3, PSMA, and EGFR transcripts in cells captured on magnetic beads. The DDPCR assay can be processed up to 7 days after a draw and detects KLK2, KLK3, HOXB13, GRHL2, and FOXA1 genes. AdnaTest and DDPCR were considered positive if at least 1 transcript was detected. AdnaTest detected CTCs in 34 samples (62%; 95% confidence interval [CI], 48%–75%), of which 23 (68%) had unfavorable CTC counts by CellSearch. A positive DDPCR result was seen in 38 cases (69%; 95% CI, 55%–81%), including 24 (63%) with unfavorable CellSearch CTC counts. CellSearch found unfavorable CTC counts in 25 samples (45%; 95% CI, 33%–58%). Sensitivities were similar between the AdnaTest and DDPCR assays, and both were more sensitive than CellSearch. Concordance probability estimates (possible values, 0.5–1.0) associating the biomarker result with survival were similar: 0.77 (SE, 0.07) for AdnaTest, 0.72 (SE, 0.08) for DDPCR, and 0.76 (SE, 0.06) for CellSearch. Overall detection rates between the AdnaTest and DDPCR assays were similar, and both were superior to CellSearch. The DDPCR assay required the lowest blood volume, least on-site processing, and longest stability for batch processing.","PeriodicalId":22430,"journal":{"name":"The Cancer Journal","volume":"12 1","pages":"315–320"},"PeriodicalIF":0.0000,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"48","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Cancer Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/PPO.0000000000000220","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 48

Abstract

AbstractCirculating tumor cell (CTC) number measured with the CellSearch assay is prognostic for survival in metastatic castration-resistant prostate cancer before and after therapy. Using a standard operating protocol for sample collection, processing, and analysis, we compared detection rates of CellSearch performed using US Food and Drug Administration–cleared methodology with a second positive selection assay, AdnaTest, and a nonselection polymerase chain reaction (PCR)–based (direct detection PCR [DDPCR]) assay in 55 blood samples from 47 men with progressive metastatic castration-resistant prostate cancer. AdnaTest requires processing within 4 hours of the draw and detects KLK3, PSMA, and EGFR transcripts in cells captured on magnetic beads. The DDPCR assay can be processed up to 7 days after a draw and detects KLK2, KLK3, HOXB13, GRHL2, and FOXA1 genes. AdnaTest and DDPCR were considered positive if at least 1 transcript was detected. AdnaTest detected CTCs in 34 samples (62%; 95% confidence interval [CI], 48%–75%), of which 23 (68%) had unfavorable CTC counts by CellSearch. A positive DDPCR result was seen in 38 cases (69%; 95% CI, 55%–81%), including 24 (63%) with unfavorable CellSearch CTC counts. CellSearch found unfavorable CTC counts in 25 samples (45%; 95% CI, 33%–58%). Sensitivities were similar between the AdnaTest and DDPCR assays, and both were more sensitive than CellSearch. Concordance probability estimates (possible values, 0.5–1.0) associating the biomarker result with survival were similar: 0.77 (SE, 0.07) for AdnaTest, 0.72 (SE, 0.08) for DDPCR, and 0.76 (SE, 0.06) for CellSearch. Overall detection rates between the AdnaTest and DDPCR assays were similar, and both were superior to CellSearch. The DDPCR assay required the lowest blood volume, least on-site processing, and longest stability for batch processing.
AdnaTest法检测循环肿瘤细胞与直接检测稳定全血中肿瘤mRNA作为预测转移性去势抵抗前列腺癌患者总生存的生物标志物的临床有效性
【摘要】CellSearch检测循环肿瘤细胞(CTC)数量是治疗前后转移性去势抵抗性前列腺癌患者生存的预后指标。使用标准的样本收集、处理和分析操作方案,我们比较了使用美国食品和药物管理局(fda)批准的方法进行的CellSearch的检出率,与第二种阳性选择试验AdnaTest和基于非选择聚合酶链反应(PCR)的(直接检测PCR [DDPCR])方法在47名进展性转移性去势抵抗性前列腺癌男性的55份血液样本中的检出率。AdnaTest需要在提取后4小时内进行处理,并检测磁珠捕获的细胞中的KLK3, PSMA和EGFR转录本。DDPCR检测可在提取后7天内进行,检测KLK2、KLK3、HOXB13、GRHL2和FOXA1基因。如果检测到至少1个转录物,则认为AdnaTest和DDPCR阳性。AdnaTest在34份样本中检测到ctc (62%;95%可信区间[CI], 48%-75%),其中23例(68%)CellSearch的CTC计数不理想。DDPCR阳性38例(69%;95% CI, 55%-81%),包括24例(63%)CellSearch CTC计数不理想。CellSearch在25个样本中发现不利的CTC计数(45%;95% ci, 33%-58%)。AdnaTest和DDPCR检测之间的敏感性相似,两者都比CellSearch更敏感。生物标志物结果与生存相关的一致性概率估计(可能值,0.5-1.0)相似:AdnaTest为0.77 (SE, 0.07), DDPCR为0.72 (SE, 0.08), CellSearch为0.76 (SE, 0.06)。AdnaTest和DDPCR检测的总体检出率相似,均优于CellSearch。DDPCR检测需要最少的血容量,最少的现场处理和最长的稳定性进行批量处理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信